EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

mRNA-based cancer vaccines for cancer immunotherapy: current progress, challenges, and emerging opportunities

Shweta Kulshreshtha, Umesh Kumar, V. V. Sathibabu Uddandrao, Shoorvir Singh, Akshata Mandloi, Himanshu Gogoi

Frontiers in Pharmacology · 10.11.2026 · 17

DOI: 10.3389/fphar.2026.1984876 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.11.2026. Verfasst von Shweta Kulshreshtha und 5 weiteren Autor:innen. Die Arbeit nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mRNA-based cancer vaccines have emerged as a promising platform for therapeutic cancer immunotherapy because of their ability to encode tumor-associated antigens, tumor-specific antigens, and patient-specific neoantigens and to induce antigen-specific immune responses. Their flexible and cell-free manufacturing enables rapid adaptation and facilitates the development of personalized vaccines based on individual tumor mutations and HLA profiles. However, the clinical translation of mRNA-based cancer vaccines remains challenging because of difficulties in neoantigen identification, maintaining mRNA stability, achieving efficient intracellular and tissue-specific delivery and endosomal escape, optimizing antigen expression, and overcoming tumor heterogeneity, and immunosuppressive tumor microenvironments. Advances in mRNA engineering, including sequence optimization, modified nucleosides, cap and UTR optimization, and lipid nanoparticle-based delivery, have improved RNA stability, cellular uptake, antigen expression, and immune activation in various experimental and clinical settings. This review discusses the principles of mRNA-based cancer vaccines, strategies for neoantigen identification and vaccine development, mRNA production and formulation, nanoparticle-mediated delivery, major challenges affecting stability, targeting, expression, and immune stimulation, and emerging clinical applications. Particular emphasis is placed on personalized neoantigen vaccines and combination approaches with immune checkpoint inhibitors. Continued integration of RNA engineering, nanotechnology, computational antigen prediction, and precision immunotherapy may enable more effective and clinically adaptable mRNA-based cancer vaccines.

Zitieren

APA

Kulshreshtha, S., Kumar, U., Uddandrao, V. V. S., Singh, S., Mandloi, A., & Gogoi, H. (2026). mRNA-based cancer vaccines for cancer immunotherapy: current progress, challenges, and emerging opportunities. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1984876

Vancouver

Kulshreshtha S, Kumar U, Uddandrao VVS, Singh S, Mandloi A, Gogoi H. mRNA-based cancer vaccines for cancer immunotherapy: current progress, challenges, and emerging opportunities. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1984876

BibTeX
@article{Kulshreshtha2026,
  author = {Kulshreshtha, Shweta and Kumar, Umesh and Uddandrao, V. V. Sathibabu and Singh, Shoorvir and Mandloi, Akshata and Gogoi, Himanshu},
  title = {mRNA-based cancer vaccines for cancer immunotherapy: current progress, challenges, and emerging opportunities},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1984876}
}
Kostenlos starten →